UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER

被引：1

作者：

Hays, John ^{[1
]}

Werner, Theresa ^{[2
]}

Lakhani, Nehal ^{[3
]}

Edenfield, Jeffrey ^{[4
]}

Buscema, Joseph ^{[5
]}

Burns, Timothy ^{[6
]}

Carrington, Cassandra ^{[7
]}

Keeton, Erika ^{[8
]}

Burger, Robert ^{[9
]}

Anderson, Charles ^{[10
]}

机构：

[1] Ohio State Univ, James Canc Ctr, Med Oncol, Columbus, OH 43210 USA

[2] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA

[3] Canc & Hematol Ctr Western Michigan, Med Oncol, Grand Rapids, MI USA

[4] Univ South Carolina, Greenville Hosp Syst Univ Med Ctr, Med Oncol, Greenville, SC USA

[5] Arizona Oncol Associates, Gynecol Oncol, Tucson, AZ USA

[6] Univ Pittsburgh, Med Oncol, Pittsburgh, PA USA

[7] Mersana Therapeut, Cambridge, MA USA

[8] Mersana Therapeut, Clin Res, Cambridge, MA USA

[9] Mersana Therapeut, Clin Dev, Cambridge, MA USA

[10] Willamette Valley Canc Inst & Res Ctr, Med Oncol, Eugene, OR USA

来源：

关键词：

D O I：

10.1136/ijgc-2022-igcs.533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TP024/#446

引用

页码：A235 / A235

页数：1